title: Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations.
abstract: OBJECTIVE
  In contrast to in vitro studies, most clinical trials testing the radiosensitivity of BRCA (Breast cancer susceptibility gene) mutations do not find a correlation between BRCA status and enhanced radiosensitivity. These trials include different ethnicities, and there is a lack of clinical data on BRCA1/2 mutation carriers and radiosensitivity in non-Caucasian patients. The goal of this study was to investigate acute skin toxicity, as a part of radiosensitivity, in breast cancer patients with BRCA1/2 mutations.
  
  
  METHODS
  BRCA mutation analysis was performed for 213 patients who underwent breast-conserving therapy using radiotherapy. Skin toxicity was scored according to the Radiation Therapy Oncology Group (RTOG) criteria during treatment and during one-month follow-up after radiation therapy.
  
  
  RESULTS
  Forty-six patients had BRCA1/2 mutations and 57 patients showed higher than grade 2 (RTOG) skin toxicity. In multivariate analysis, significant associations were found between mean breast volume and acute skin toxicity. BRCA mutation status, however, failed to show a significant correlation.
  
  
  CONCLUSIONS
  Our results indicate that carriers of BRCA1/2 mutations among non-Caucasian breast cancer patients showed no enhancement in radiation sensitivity. Multiple genetic markers may be correlated with normal tissue responses after radiotherapy. Further studies are needed to identify genetic predispositions to normal tissue responses after radiotherapy.
authors: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.
authors: Hyojung
authors: H
authors: Park
authors: Doo Ho
authors: DH
authors: Choi
authors: Jae Myoung
authors: JM
authors: Noh
authors: Seung Jae
authors: SJ
authors: Huh
authors: Won
authors: W
authors: Park
authors: Seok-Jin
authors: SJ
authors: Nam
authors: Jeong Eon
authors: JE
authors: Lee
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000532:radiotherapy*; D015984:Causality; D015897:Comorbidity; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D011836:Radiation Tolerance; D011855:Radiodermatitis / Q000453:epidemiology* / Q000235:genetics* / Q000503:physiopathology; D020266:Radiotherapy, Conformal; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome; D044767:Ubiquitin-Protein Ligases / Q000235:genetics*
chemical_list: D024682:BRCA2 Protein; C551750:BRCA2 protein, human; C111164:BRAP protein, human; D044767:Ubiquitin-Protein Ligases